<DOC>
	<DOC>NCT02137746</DOC>
	<brief_summary>The purpose of this study is to assess the safety of the second cycle of DCVAC/PCa in patients who completed the first cycle of DCVAC/PCa in the clinical trial SP003 without an objective progression of the disease.</brief_summary>
	<brief_title>Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>Same as brief summary</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male 18 years and older Histologically confirmed prostate adenocarcinoma Stage pathological tumor2 (pT2) Post radical Primary Prostatectomy Completion of DCVAC/PCa arm in Study SP003, without objective progression of the disease Prior androgen deprivation therapy for prostate cancer Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater Other uncontrolled intercurrent illness Treatment with immunotherapy against PCa Clinically significant cardiovascular disease Active autoimmune disease requiring treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Radical Prostatectomy</keyword>
</DOC>